Skip to main content

Generics

  • Watson's revenue grows 25%

    SAN FRANCISCO — Though it plans to announce its fiscal year 2010 results next month, Watson Pharmaceuticals offered a peak at some preliminary numbers at the 29th annual J.P. Morgan Healthcare Conference Wednesday.

    Watson said that based on a review of results for last year, it expects to have earned revenues of more than $3.5 billion, a 25% increase over 2009.

  • Older physicians less likely to prescribe generic medications

    WOONSOCKET, R.I. — While a majority of physicians are comfortable with generic medications, there is a small segment who still have negative perceptions about the effectiveness and quality of generic drugs, and that may lead to doctors prescribing unnecessarily expensive medications, according to a new study by researchers at Harvard University, Brigham and Women's Hospital and CVS Caremark.

  • BB&T rescinds mandatory mail Rx proposal, drawing praise from independent pharmacies

    ALEXANDRIA, Va. — The nation’s top independent pharmacy group is hailing a recent decision by a major corporation to maintain freedom of choice of where its employees fill their maintenance prescription medicines.

    The National Community Pharmacists Association today applauded BB&T's decision to reemphasize and continue its employees' choice in filling their maintenance prescriptions, including at independent community pharmacies. The revised policy was communicated to BB&T employees last week.

  • Watson's generic Fentora gets FDA approval

    MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic drug made by Watson Pharmaceuticals for cancer-related pain, Watson said Monday.

    Watson announced the approval of fentanyl buccal tablets in the 0.1-mg, 0.2-mg, 0.6-mg and 0.8-mg strengths.

  • Sandoz contraceptive granted regulatory approval

    PRINCETON, N.J. — The Food and Drug Administration has approved a generic contraceptive made by Sandoz, the company said.

    Sandoz, the generics arm of Swiss drug maker Novartis, announced the FDA approval of Introvale (levonorgestrel and ethinyl estradiol), a generic version of Duramed’s Seasonale.

    Branded and generic versions of Seasonale had sales of around $91 million during the 12-month period ended in November, according to IMS Health.

  • AdventRx's application for Exelbine accepted by FDA

    SAN DIEGO — The Food and Drug Administration has accepted the approval application for a chemotherapy drug to treat lung cancer from AdventRx Pharmaceuticals, the drug maker said Thursday.

    The FDA accepted AdventRx’s application for Exelbine (vinorelbine). The drug is a branded generic, being formulated with the same active ingredient as Navelbine, originally marketed by French drug maker Pierre Fabre and now available as a generic from seven companies.

  • Spectrum, Viropro to develop biosimilar

    IRVINE, Calif. — A U.S. biotech company plans to develop a biosimilar of a monoclonal antibody used to treat cancers and autoimmune disorders.

    Spectrum Pharmaceuticals announced Wednesday a deal with Viropro to develop a biosimilar rituximab, marketed under the brand name Rituxan by Roche’s Genentech division. Global sales of rituximab in 2009 were $5.6 billion, according to Spectrum.

  • Retail pharmacy can rest easy with unequivocal AMP victory

    ALEXANDRIA, Va. — It’s a battle that raged for more than three years. But in mid-December, the retail pharmacy industry was able to declare a clear, unequivocal victory.


    We’re talking, of course, about the struggle to head off what would have been a devastating change in the way Medicaid pays community pharmacies to dispense generic drugs to low-income patients. On Dec. 14, the chain and independent pharmacy lobbies announced they had reached a landmark agreement with the 
Centers for Medicare and Medicaid Services that effectively ends the threat.

X
This ad will auto-close in 10 seconds